Heart failure is a serious condition that affects millions of people around the world. It happens when the heart cannot pump blood as well as it should. This means the body does not get enough oxygen and nutrients.
Over time, this can lead to tiredness, shortness of breath, and swelling in the body. One of the most dangerous problems in heart failure is fluid buildup in the lungs. When this happens, patients often need to go to the hospital.
A new study presented at the American College of Cardiology’s Annual Scientific Session has found a promising way to improve care for these patients. The research shows that using a simple, noninvasive device to monitor fluid in the lungs can greatly reduce hospital visits and even deaths.
In this study, researchers focused on a type of heart failure called heart failure with preserved ejection fraction, or HFpEF. This form of heart failure happens when the heart becomes stiff and cannot relax properly. As a result, it cannot fill with enough blood. This leads to pressure buildup and fluid accumulation, especially in the lungs.
The researchers followed 150 patients with this condition over more than three years. Half of the patients received standard care, which means doctors adjusted treatment based on symptoms and regular checkups. The other half received care guided by a special device called the CardioSet Edema Guard Monitor.
This device works by measuring how electricity moves through the lungs. When fluid builds up, the lungs conduct electricity differently. By tracking these changes, doctors can detect fluid buildup very early, even before symptoms appear.
The results were very strong. Patients whose treatment was guided by the device were 74% less likely to be hospitalized for heart failure. They were also 74% less likely to die from heart failure compared to those receiving standard care.
One reason for this improvement is that doctors were able to act earlier. When the device showed signs of fluid buildup, doctors adjusted medications sooner. In fact, treatment changes were made more than twice as often in the group using the device. This early action helped prevent the condition from becoming severe.
The study also showed that patients in the device group went much longer before needing their first hospital visit. On average, it took over 600 days before hospitalization, compared to just over 80 days in the standard care group.
Another important finding was that the device was safe. There were no problems or side effects linked to its use. This makes it a practical option for everyday care.
However, there are some limitations to the study. It was conducted at a single center, and more research in different locations is needed to confirm the results. In addition, one of the researchers is connected to the company that developed the device, which means the findings should be confirmed by independent studies.
Even so, the results are very promising. This approach focuses on prevention rather than reaction. Instead of waiting for symptoms to appear, doctors can act early and keep patients stable.
In simple terms, this study shows that better monitoring can lead to better outcomes. By catching problems early, doctors can reduce hospital visits and save lives.
The findings were presented at the American College of Cardiology’s Annual Scientific Session.
This research highlights an important shift in healthcare. It shows that technology can help doctors make smarter decisions and improve patient care. However, larger studies are needed before this method becomes widely used. If future research confirms these results, this device could become a key tool in managing heart failure.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and Vitamin K2 could help reduce heart disease risk.
For more information about heart health, please see recent studies about how to remove plaques that cause heart attacks, and results showing a new way to prevent heart attacks, strokes.
Source: CardioSet Medical.
